Journal list menu
Export Citations
Download PDFs
ISSUE INFORMATION
EDITORS' PERSPECTIVE
Free Access
free
Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: A (huge?) step in the right direction
- Pages: 1441-1442
- First Published: 17 June 2021
EDITORIALS
Free Access
free
The never-ending debate about conflict of interests'
- Pages: 1443-1444
- First Published: 17 June 2021
Free Access
free
Micro-elimination of hepatitis C among people living with HIV in Egypt
- Pages: 1445-1447
- First Published: 17 June 2021
REVIEWS & META-ANALYSES
Free Access
free
Antiviral prophylaxis against hepatitis B recurrence after liver transplantation: Current concepts
- Pages: 1448-1461
- First Published: 03 March 2021
Open Access
oa
Hepatitis E: An update on One Health and clinical medicine
- Pages: 1462-1473
- First Published: 07 May 2021
Free Access
free
2021 ISHEN guidelines on animal models of hepatic encephalopathy
- Pages: 1474-1488
- First Published: 26 April 2021
LIVER DISEASE AND PUBLIC HEALTH
no
Deaths from hepatocellular carcinoma are more likely to occur in medical facilities than deaths from other cancers: 2003-2018
- Pages: 1489-1493
- First Published: 01 May 2021
no
Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort
- Pages: 1494-1497
- First Published: 27 April 2021
VIRAL HEPATITIS
no
Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens
- Pages: 1498-1508
- First Published: 24 January 2021
no
Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life
- Pages: 1509-1517
- First Published: 17 May 2021
Open Access
oa
Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry
- Pages: 1518-1522
- First Published: 09 May 2021
no
Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry
- Pages: 1523-1531
- First Published: 26 October 2020
METABOLIC & TOXIC LIVER DISEASES
no
Effects of two personalized dietary strategies during a 2-year intervention in subjects with nonalcoholic fatty liver disease: A randomized trial
- Pages: 1532-1544
- First Published: 07 February 2021
no
Liver chemistries in glycogenic hepatopathy associated with type 1 diabetes mellitus: A systematic review and pooled analysis
- Pages: 1545-1555
- First Published: 17 February 2021
no
Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: A population-based study
- Pages: 1556-1564
- First Published: 17 February 2021
Open Access
oa
Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients
- Pages: 1565-1575
- First Published: 18 April 2021
GUT-LIVER AXIS, IMMUNOLOGY, IMMUNE MEDIATED AND CHOLESTATIC DISEASES
Open Access
oa
Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease
- Pages: 1576-1591
- First Published: 25 April 2021
no
Autoimmune hepatitis in patients aged 70 years or older: Disease characteristics, treatment response and outcome
- Pages: 1592-1599
- First Published: 25 April 2021
GENETICS AND RARE LIVER DISEASES
Open Access
oa
Prolonged exposure to welding fumes as a novel cause of systemic iron overload
- Pages: 1600-1607
- First Published: 13 March 2021
CIRRHOSIS, LIVER FAILURE AND TRANSPLANTATION
Open Access
oa
Histological sub-classification of cirrhosis using collagen proportionate area in patients with chronic hepatitis C
- Pages: 1608-1613
- First Published: 24 April 2021
no
Circulating extracellular vesicles induce monocyte dysfunction and are associated with sepsis and high mortality in cirrhosis
- Pages: 1614-1628
- First Published: 13 March 2021
no
Sarco-Model: A score to predict the dropout risk in the perspective of organ allocation in patients awaiting liver transplantation
- Pages: 1629-1640
- First Published: 01 April 2021
LIVER CANCER
no
Clinicopathologic and MRI features of combined hepatocellular-cholangiocarcinoma in patients with or without cirrhosis
- Pages: 1641-1651
- First Published: 27 January 2021
no
Twelve-month post-treatment parameters are superior in predicting hepatocellular carcinoma in patients with chronic hepatitis B
- Pages: 1652-1661
- First Published: 07 February 2021
no
Pathological predictive factors for late recurrence of hepatocellular carcinoma in chronic liver disease
- Pages: 1662-1674
- First Published: 27 February 2021
LIVER INTERNATIONAL IMAGES
no
The seat of life. What a lesson from the stigmatized saints
- Pages: 1675-1676
- First Published: 13 January 2021
EXPERIMENTAL HEPATOLOGY
no
SPARC inhibition accelerates NAFLD-associated hepatocellular carcinoma development by dysregulating hepatic lipid metabolism
- Pages: 1677-1693
- First Published: 28 February 2021
RESEARCH LETTER
no
Liver fibrosis and all-cause mortality in chronic HCV-infected diabetic patients: A paradoxical association? (ANRS CO22 HEPATHER)
- Pages: 1694-1698
- First Published: 16 May 2021
LETTERS TO THE EDITOR
no
Microvascular invasion, an important clinical feature that should be deeply explored in hepatocellular carcinoma
- Page: 1699
- First Published: 25 April 2021
no
On-treatment predictors of hepatocellular carcinoma in patients with chronic hepatitis B
- Pages: 1700-1701
- First Published: 09 May 2021
no
Liver dysfunction of Atezolizumab + Bevacizumab -a matter of life or death−
- Pages: 1702-1703
- First Published: 28 May 2021